atrasentan has been researched along with bay 94-8862 in 2 studies
| Studies (atrasentan) | Trials (atrasentan) | Recent Studies (post-2010) (atrasentan) | Studies (bay 94-8862) | Trials (bay 94-8862) | Recent Studies (post-2010) (bay 94-8862) |
|---|---|---|---|---|---|
| 358 | 41 | 108 | 183 | 37 | 179 |
| Protein | Taxonomy | atrasentan (IC50) | bay 94-8862 (IC50) |
|---|---|---|---|
| Mineralocorticoid receptor | Homo sapiens (human) | 0.0275 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Batu Demir, D; Cooper, ME | 1 |
| Heerspink, HJL; Muskiet, MHA; Wheeler, DC | 1 |
2 review(s) available for atrasentan and bay 94-8862
| Article | Year |
|---|---|
New strategies to tackle diabetic kidney disease.
Topics: Angiotensin II Type 2 Receptor Blockers; Antihypertensive Agents; Atrasentan; Diabetes Mellitus; Diabetic Nephropathies; Dipeptidyl-Peptidase IV Inhibitors; Disease Progression; Endothelin Receptor Antagonists; Humans; Hypoglycemic Agents; Kidney Failure, Chronic; Mineralocorticoid Receptor Antagonists; Naphthyridines; Pyrrolidines; Renal Artery; Renal Insufficiency, Chronic; Sodium-Glucose Transporter 2 Inhibitors; Sympathectomy | 2016 |
New pharmacological strategies for protecting kidney function in type 2 diabetes.
Topics: Antihypertensive Agents; Atrasentan; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Endothelin Receptor Antagonists; Humans; Hypoglycemic Agents; Incretins; Mineralocorticoid Receptor Antagonists; Naphthyridines; Renal Insufficiency, Chronic; Sodium-Glucose Transporter 2 Inhibitors | 2019 |